BR112015029293A2 - método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero - Google Patents

método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero

Info

Publication number
BR112015029293A2
BR112015029293A2 BR112015029293A BR112015029293A BR112015029293A2 BR 112015029293 A2 BR112015029293 A2 BR 112015029293A2 BR 112015029293 A BR112015029293 A BR 112015029293A BR 112015029293 A BR112015029293 A BR 112015029293A BR 112015029293 A2 BR112015029293 A2 BR 112015029293A2
Authority
BR
Brazil
Prior art keywords
delaying
mammal
disorder
kit
treating
Prior art date
Application number
BR112015029293A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhou Mingdong
Original Assignee
Zensun Shanghai Science & Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science & Tech Ltd filed Critical Zensun Shanghai Science & Tech Ltd
Publication of BR112015029293A2 publication Critical patent/BR112015029293A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
BR112015029293A 2013-05-22 2014-05-22 método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero BR112015029293A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361826433P 2013-05-22 2013-05-22
PCT/CN2014/078154 WO2014187342A1 (en) 2013-05-22 2014-05-22 Extended Release of Neuregulin for Treating Heart Failure

Publications (1)

Publication Number Publication Date
BR112015029293A2 true BR112015029293A2 (pt) 2018-04-24

Family

ID=51932900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029293A BR112015029293A2 (pt) 2013-05-22 2014-05-22 método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero

Country Status (11)

Country Link
US (4) US10098834B2 (enExample)
EP (3) EP2999499B1 (enExample)
JP (2) JP6568052B2 (enExample)
KR (3) KR20230132635A (enExample)
CN (2) CN105611955A (enExample)
AU (2) AU2014270882B2 (enExample)
BR (1) BR112015029293A2 (enExample)
CA (1) CA2911848A1 (enExample)
ES (1) ES2743617T3 (enExample)
RU (1) RU2015154737A (enExample)
WO (1) WO2014187342A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
CN111840517A (zh) * 2019-04-28 2020-10-30 上海泽生科技开发股份有限公司 神经调节蛋白用于长效预防、治疗或延迟心脏损伤的方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
CA2126619A1 (en) 1993-06-24 1994-12-25 Yasutaka Igari Sustained-release preparation of anti-endothelin substance
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2000502682A (ja) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
AU732027B2 (en) 1997-02-10 2001-04-12 Genentech Inc. Heregulin variants
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AU2001241839A1 (en) 2000-02-28 2001-09-12 Decode Genetics Ehf Human schizophrenia gene
US20010041869A1 (en) 2000-03-23 2001-11-15 Causey James D. Control tabs for infusion devices and methods of using the same
US20050277887A1 (en) * 2000-05-08 2005-12-15 Joel Douglas Micro infusion drug delivery device
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
US7375185B2 (en) 2000-09-12 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002048191A2 (en) 2000-12-11 2002-06-20 Yeda Research And Development Co. Ltd. Inhibitory agents derived from specific growth factors
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
JP2005500025A (ja) * 2001-05-29 2005-01-06 サーナ・セラピューティクス・インコーポレイテッド 女性生殖疾病及び状態の核酸に基づく調節
WO2003035095A1 (en) 2001-10-19 2003-05-01 Maxim Pharmaceuticals, Inc. Use of histamine to treat liver disease
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7128727B2 (en) 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
US7144384B2 (en) 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
US20060275770A1 (en) 2002-11-27 2006-12-07 Daniel Bednarik Heart failure gene determination and therapeutic screening
BRPI0410787A (pt) 2003-05-21 2006-06-20 Univ Texas inibição da proteìna cinase c-mu (pkd) como um tratamento para hipertrofia cardìaca e insuficiência cardìaca
US20050065760A1 (en) 2003-09-23 2005-03-24 Robert Murtfeldt Method for advising patients concerning doses of insulin
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
CN1743005A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Pi3－k抑制剂的新用途及组合物
CN1743006A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Mapk抑制剂的新用途及组合物
US20080213395A1 (en) 2004-10-14 2008-09-04 Adventures Plus Pty Ltd Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
US7686787B2 (en) 2005-05-06 2010-03-30 Medtronic Minimed, Inc. Infusion device and method with disposable portion
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN101310779A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN101310766B (zh) 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
CN102470161A (zh) * 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
WO2010142141A1 (en) * 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2011112864A1 (en) 2010-03-10 2011-09-15 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
KR101800040B1 (ko) * 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
CN108420827A (zh) 2010-07-22 2018-08-21 雷文制药有限公司 包含磁偶极子稳定化溶液的组合物及其用途
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
US20160129084A1 (en) 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AT521173B1 (de) 2018-06-27 2019-11-15 Trumpf Maschinen Austria Gmbh & Co Kg Biegewerkzeug mit Distanzelement

Also Published As

Publication number Publication date
JP6568052B2 (ja) 2019-09-04
US20160089329A1 (en) 2016-03-31
CA2911848A1 (en) 2014-11-27
CN112168953A (zh) 2021-01-05
EP3895724A1 (en) 2021-10-20
RU2015154737A (ru) 2017-06-27
ES2743617T3 (es) 2020-02-20
JP2016520089A (ja) 2016-07-11
EP2999499B1 (en) 2019-07-17
RU2015154737A3 (enExample) 2018-04-26
AU2014270882A1 (en) 2015-11-26
AU2019203799B2 (en) 2021-05-20
KR20160009575A (ko) 2016-01-26
US20190240145A1 (en) 2019-08-08
AU2014270882B2 (en) 2019-03-14
KR20220018076A (ko) 2022-02-14
KR102357275B1 (ko) 2022-02-03
EP3610905B1 (en) 2021-03-31
KR102578135B1 (ko) 2023-09-13
EP2999499A4 (en) 2017-01-18
US12208158B2 (en) 2025-01-28
EP2999499A1 (en) 2016-03-30
US20250360078A1 (en) 2025-11-27
WO2014187342A1 (en) 2014-11-27
JP2019172689A (ja) 2019-10-10
EP3895724B1 (en) 2025-06-25
KR20230132635A (ko) 2023-09-15
EP3610905A1 (en) 2020-02-19
US20220211613A1 (en) 2022-07-07
US10098834B2 (en) 2018-10-16
US11179323B2 (en) 2021-11-23
CN105611955A (zh) 2016-05-25
AU2019203799A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
BR112015006996A2 (pt) método para reduzir a quantidade de enxofre em uma composição que compreende enxofre, e, composição.
IL241309B (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
AP2016009549A0 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
DE112014000254T8 (de) Mehrstufiges Zwischenspeichern und Migrieren in unterschiedlichen Granularitäten
DK3777595T3 (da) Integrerede lukkeanordningskomponenter og fremgangsmåder
SI3394065T1 (sl) Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega
BR112014007619A2 (pt) composição cosmética, e, método para melhorar pelo menos uma propriedade
FI20115893L (fi) Menetelmä retention säätämiseksi ja menetelmässä käytettävä välituote
BR302013005965S1 (pt) Configuração aplicada em otomana
ZA201505875B (en) Compositions and methods for treating and repairing tendons
EP2981554A4 (en) Methods and compositions for treating and preventing disease associated with avb8 integrin
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
BR112014013990A2 (pt) retardador hidrodinâmico desconectável e método para controlar o mesmo
IL239715A0 (en) Methods of treatment of fibrosis and cancers
HUE042792T2 (hu) Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére
BR302013005862S1 (pt) Configuração aplicada em coador
BR112015005335A2 (pt) composição farmacêutica para tratar uma ferida, método para tratar uma ferida, composição farmacêutica contida em uma embalagem e kit para tratar uma ferida em um sujeito
FI20155623A7 (fi) Järjestely ja menetelmä kuorman säätämiseksi harjoitteluvälineessä
PT3027213T (pt) Composições para melhorar e/ou prevenir efeitos colaterais adversos em antibioterapia
BR112014032456A2 (pt) métodos in vitro, composição farmacêutica, kit para realização do método e método para melhorar o efeito de tratamento
EP3036019A4 (en) SNOWBOARD WITH MODIFIED RAILS AND EDGES
BR302012006743S1 (pt) Configuração aplicada em estojo para curativos
BR302014002623S1 (pt) Configuração introduzida em componente luminoso
BR112018008893A2 (pt) método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ZENSUN (SHANGHAI) SCIENCE AND TECHNOLOGY, CO., LTD

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]